FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

28 letters match. Newest first.

  1. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk
  2. Auriga Research Pvt. Ltd.

    Auriga Research, an Indian contract drug testing lab, failed to keep complete lab records and properly investigate failing test results.

    High risk
  3. Island Kinetics, Inc. d.b.a. CoValence Laboratories

    Island Kinetics (CoValence Laboratories) made OTC acne drugs without process validation and shipped unapproved, misbranded acne products.

    High risk
  4. Boothwyn Pharmacy, LLC

    Boothwyn Pharmacy made sterile drugs in insanitary conditions and shipped lots that failed sterility and potency tests.

    High risk
  5. Tower Laboratories Ltd.

    FDA warned Tower Laboratories, an OTC drug maker in Montague, MI, for weak out-of-specification investigations and unproven test methods.

    High risk
  6. Unipack LLC

    FDA says Unipack LLC released suppositories without adequate out-of-specification investigations, complete lab records, and required USP testing.

    High risk
  7. SV Labs Corporation

    SV Labs released microbe-contaminated OTC drug products and lacked water, process and quality controls, FDA says.

    High risk
  8. Rhyz Analytical Labs

    FDA warned Rhyz Analytical Labs, a contract drug testing lab, that inadequate microbial failure investigations and quality oversight made tested drugs adulterated.

    High risk
  9. Cdymax India Pharma Private Limited

    FDA warned Cdymax (India) Pharma that its Bangalore API plant had inadequate out-of-specification investigations and unvalidated test methods, making its APIs adulterated.

    High risk
  10. Liebel-Flarsheim Company LLC

    Liebel-Flarsheim's Raleigh, NC sterile drug plant failed to investigate microbial and endotoxin test failures and let cleanrooms and equipment fall into disrepair.

    High risk
  11. Persōn & Covey, Inc.

    FDA cites Persōn & Covey for CGMP failures at its Glendale, CA drug plant and for selling unapproved Xerac AC and Drysol.

    High risk
  12. Columbia Cosmetics Manufacturing Inc.

    Columbia Cosmetics Manufacturing Inc. made OTC sunscreen drugs without adequate current good manufacturing practice, including failed out-of-specification investigations and untested high-risk ingredients.

    High risk
  13. Integra LifeSciences Corporation

    FDA warned Integra LifeSciences over bacterial toxin test and sterilization failures at three medical device plants.

    High risk
  14. Seatex, LLC

    Seatex, LLC made OTC hand sanitizer drugs with inadequate current good manufacturing practice (CGMP), including shared equipment with industrial chemicals and missing component testing.

    High risk
  15. Antaria Pty. Ltd.

    FDA warned Antaria Pty. Ltd. about manufacturing quality failures in its active drug ingredient, including poor out-of-specification investigations and testing.

    High risk
  16. Bell International Laboratories, Inc.

    Bell International Laboratories, an OTC drugmaker, was cited for manufacturing rule violations including missing glycerin DEG/EG testing and inadequate quality oversight.

    High risk
  17. ALI Pharmaceutical Manufacturing, LLC

    FDA says ALI Pharmaceutical Manufacturing failed to validate and control its porcine thyroid drug substance process, making the drug substance adulterated.

    High risk
  18. Medgel Private Limited

    FDA cited Medgel Private Limited, an Indian OTC drug maker, for manufacturing violations including poor investigations and data integrity failures.

    High risk
  19. EarthLab, Inc., dba Wise Woman Herbals

    FDA warned EarthLab, doing business as Wise Woman Herbals, over unapproved drug claims and supplement CGMP violations.

    High risk
  20. Aspire Pharmaceuticals, Inc.

    FDA warning letter to Aspire Pharmaceuticals cites dietary supplement and drug CGMP violations, including falsified lab data and missing impurity testing.

    High risk
  21. Episciences Inc.

    FDA warns Episciences Inc. that its Boise, Idaho plant made OTC drugs without adequate batch testing, process validation and failure investigations.

    High risk
  22. Monarch PCM, LLC

    Monarch PCM, LLC made unapproved skin drugs and broke manufacturing rules, with microbial contamination and weak investigations.

    High risk
  23. Ultra Seal Corporation

    FDA warns Ultra Seal and ULTRAtab over manufacturing quality failures in over-the-counter drug cleaning, testing, and release.

    High risk
  24. Yusef Manufacturing Laboratories, LLC

    FDA warned Yusef Manufacturing Laboratories over serious CGMP violations in its OTC drugs and hand sanitizers, including untested ethanol.

    High risk
  25. Accu Bio-Chem Laboratories

    FDA warned Accu Bio-Chem Laboratories, a contract OTC drug-testing lab, over inadequate failing-result investigations, method verification, and data controls.

    Medium
  26. Hubei Kangzheng Pharmaceutical Co., Ltd.

    FDA warns Hubei Kangzheng over non-sterile ophthalmic drops, CGMP failures, and unapproved/misbranded pi yen chin.

    High risk
  27. Missouri Analytical Laboratories Inc

    Missouri Analytical Laboratories, a contract drug testing lab, cited for manufacturing practice violations including inadequate out-of-specification investigations and data integrity failures.

    High risk
  28. Allay Pharmaceuticals, LLC

    FDA warned Allay Pharmaceuticals over CGMP failures and sub-potent tablets, and distribution of an unapproved biological product.

    High risk